Because new medicines have such a high burden of R&D costs to recuperate, their commercialisation in a protected environment is essential to the innovator business model. That protection has historically been offered through the patent system, but for how much longer, given the increasing time taken to innovate?
We expected the publication of the article on the synergy of therapeutic indication and choice of presentation or choice of active ingredient to elicit quite a lot of interest, but in the event, the enquiries we have received surpassed our expectations. Visitors to our website will already have seen some of the strategy aspects, without […]
There are (at least) two camps for drug repurposing, which can be usefully divided into the on-target and the off-target categories. ‘Off-target’ repurposing may be compared to the multi-facted roles for a mobile phone, wherein the same object has the attributes of a camera and a telephonic device. ‘On-target’ repurposing is akin to the adoption […]
Pharmaceutical R&D does not always start with soup and end with nuts, although by analogy this is the classic route followed by what is now the large multinational sector of the industry. A shortcut version of the full programme is followed by generics companies and specialty pharma, who prefer to delay until the entrÃ©e is […]
There may be interesting cases…where the combination of a low-risk deuterated active can be combined with a new therapeutic use, and synergistically deliver a new product that is medically advantageous and significantly differentiated.
At the Society for Biomolecular Sciences meeting in Lille in April 2009, time was set aside for a symposium on drug repurposing. In addition to Numedicus, there were talks from Didier Leroy for the Medicines for Malaria Venture, and from Chris Lipinski, of Melior Discovery. Melior operate a two-part strategy, to provide screening services for […]
You can subscribe to the newsletter here. The Numedicus blog aims to discuss all things relevant to drug repurposing/therapeutic switching. Numedicus is found on the web at http://www.numedicus.co.uk. It is written by David Cavalla, whose picture and brief biographical details are found here.
Originally approved for an orphan disease, Glivec now has over 9 approvals and is a billion dollar product. Could another approval for diabetes further increase the commercial potential of this drug?